| Autor: |
Catherine J. Wu, Robert J. Soiffer, Jerome Ritz, Ellis L. Reinherz, Tetsuro Sasada, Vladimir Brusic, Christine M. Canning, James G. Rheinwald, Edwin P. Alyea, Shelby A. Rogers, Wanyong Zeng, Jaewon Choi, Wandi Zhang |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1078-0432.c.6518918 |
| Popis: |
Purpose: The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized.Experimental Design: We examined responses developing against CML66, an immunogenic antigen preferentially expressed in myeloid progenitor cells identified from a patient with chronic myelogenous leukemia who attained long-lived remission following CD4+ donor lymphocyte infusion (DLI).Results: From this patient, CML66-reactive CD8+ T-cell clones were detected against an endogenously presented HLA-B*4403–restricted epitope (HDVDALLW). Neither CML66-specific antibody nor T-cell responses were detectable in peripheral blood before DLI. However, by 1 month after DLI, CD8+ T cells were present in peripheral blood and at 10-fold higher frequency in marrow. Subsequently, plasma antibody to CML66 developed in association with disease remission. Donor-derived CML66-reactive T cells were detected at low levels in vivo in marrow before DLI by ELISpot and by a nested PCR-based assay to detect clonotypic T-cell receptor sequences but not in blood of the patient pre-DLI nor of the graft donor.Conclusions: CD4+ DLI results in rapid expansion of preexisting marrow-resident leukemia-specific donor CD8+ T cells, followed by a cascade of antigen-specific immune responses detectable in blood. Our single-antigen analysis thus shows that durable posttransplant tumor immunity is directed in part against nonpolymorphic overexpressed leukemia antigens that elicit coordinated cellular and humoral immunity. Clin Cancer Res; 16(10); 2729–39. ©2010 AACR. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
